PrEP

Apretude is an antiretroviral drug that inhibits HIV replication by binding to the active site of integrase and blocking the strand transfer step of retroviral DNA integration.

Pharmacists play an important role in providing education and support with adherence to PrEP in populations with a high risk for HIV infection.

Data from a recent survey reflect a resounding shift toward the role of pharmacies becoming sites for primary care.

NRTIs TAF and TDF are increasingly being used as preexposure prophylaxis (PrEP) to prevent HIV around the world.

Study findings provide insight into factors preventing the uptake of pre-exposure prophylaxis for HIV among Black female adolescents and emerging adults and provide potential strategies to improve uptake.

Although progress has been made in pre-exposure prophylaxis use, there are still significant barriers for many patients.

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

Study finds urgent need for aggressive expansion of pre-exposure prophylaxis among people who inject drugs to reduce the spread of HIV.

Due to the correlation between virologic suppression and antiretroviral therapy adherence, understanding the impediments of adherence is of the utmost importance.

Challenges for uptake of long-acting injectable pre-exposure prophylaxis in populations at risk for HIV include fear of needles, potential adverse effects, and concerns about diminished efficacy.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Although the number of new HIV infections in the world have declined, there are still regions that are geographically heterogenous that have reported an increase in infection rates.

Although clinicians cited lack of time as a reason for not using patient-reported outcomes, patients with HIV viewed their use very positively.

However, lack of access and awareness about pre-exposure prophylaxis, medication cost, and underestimating disease risk are all barriers to PrEP.

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.

Revised program will analyze the once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in adults with HIV-1 infection.

The effective preventive treatment could reduce HIV rates but needs greater access and affordability, especially among Black and Latino populations, investigators contend.

The bill allows pharmacists to dispense and administer drugs, order laboratory tests, and consult patients on HIV pre- and post-exposure drugs.

Preexposure prophylaxis should be consistently offered alongside HIV prevention services and treatment for substance abuse, investigators say.

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor that is not yet approved by any regulatory authority.

PrEP therapy has revolutionized HIV treatment by protecting patients who are high risk for acquiring the virus.

PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.

Cabotegravir is the only current HIV-1 PrEP medication that does need to be taken daily.

PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.

Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

Study results show that those who completed CBT-AD sessions were more than 2.5 times more likely to achieve undetectable viral loads than those who underwent the usual care.